BRAF and cancer: Such adaptive resistance mechanisms are suggested in many cancer cells as well as in induced pluripotent cancer cells (iPCCs) which are highly resistant to the RAS/BRAF/ERK kinase pathway inhibitors vemurafenib and trametinib [37].